StockData
CRISPR Therapeutics AG logo

CRISPR Therapeutics AG (CRSP) stock

CRSPNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 8/30
$40.15−0.22 (-0.54%)

Close on Nov 17, 2026Market cap $3.88BP/E –Yield –

CRISPR Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

CRISPR Therapeutics's price to sales ratio was 330.2× on Nov 11, 2026, against 83.2× a year earlier. Over the last 5 years it ranged from 4.2× to 411.3×, with a median of 29.4×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 2026330.2×+201.8
2025Dec 31, 2025128.4×+111.8
2024Dec 31, 202416.6×−12.7
2023Dec 29, 202329.2×−196.5
2022Dec 30, 2022225.7×+219.3
2021Dec 31, 20216.4×−133.3
2020Dec 31, 2020139.7×+123.9
2019Dec 31, 201915.8×−25.9
2018Dec 31, 201841.7×−44.4
2017Dec 29, 201786.1×+51.0
2016Dec 30, 201635.1×–

More CRISPR Therapeutics figures

See a number that looks wrong?